<DOC>
	<DOCNO>NCT01970488</DOCNO>
	<brief_summary>The purpose research study compare efficacy safety ABP 501 adalimumab ( HUMIRA® ) adult plaque psoriasis .</brief_summary>
	<brief_title>Study Compare Efficacy Safety ABP 501 Adalimumab ( HUMIRA® ) Adults With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Men woman ≥ 18 ≤ 75 year age time screen 2 . Stable moderate severe plaque psoriasis least 6 month baseline 3 . Moderate severe psoriasis define screen baseline : Body surface area ( BSA ) affect plaque psoriasis 10 % great , PASI score 12 great , static physician 's global assessment score 3 great 4 . No known history active tuberculosis 5 . Subject candidate systemic therapy phototherapy procedures 6 . Previous failure , inadequate response , intolerance , contraindication least 1 conventional antipsoriatic systemic therapy 1 . Forms psoriasis skin condition time screen visit ( eg , eczema ) 2 . Ongoing use prohibit treatment 3 . Prior use 2 biologics treatment psoriasis 4 . Previous receipt adalimumab biosimilar adalimumab Other Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Plaque Psoriasis</keyword>
</DOC>